The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerance and feasibility of chemotherapy by procarbazine, lomustine, and vincristine (PCV) for oligodendroglial anaplastic gliomas (OAG).
Marine Daros
No relevant relationships to disclose
Emeline Tabouret
No relevant relationships to disclose
Maryline Barrie
No relevant relationships to disclose
Mona Matta
No relevant relationships to disclose
Didier Autran
No relevant relationships to disclose
Celine Boucard
No relevant relationships to disclose
Marie Wertz
No relevant relationships to disclose
Dominique Figarella
No relevant relationships to disclose
Stéphane Honoré
No relevant relationships to disclose
Oliver L. Chinot
No relevant relationships to disclose